Clocoumarol is a synthetic antagonist of vitamin K, developed in the 1970s. Clocoumarol exhibits strong anticoagulant properties in rat and rabbit.

Timcodar (also known as VX-853) is a benzenepropanamide derivative patented by Vertex Pharmaceuticals Incorporated as an efflux pump inhibitor for the treatment of multi-drug resistant bacterial infection. Timcodar potentiates the activity of ethidium bromide (EtBr), a model efflux substrate, against three clinically significant gram-positive pathogens: Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae. Timcodar weakly inhibits M. tuberculosis growth in broth culture but shows a 10-fold increase in the growth inhibition of M. Tuberculosis cultured in host macrophage cells and demonstrated synergy with rifampin, moxifloxacin, and bedaquiline. In a mouse model of tuberculosis lung infection, timcodar reduces the likelihood of a relapse infection and potentiates the efficacies of rifampin and isoniazid. Timcodar in combination with Doxorubicin was studied in phase 1/2 clinical trials in patients with solid tumors, but no results have been published.

Dexindoprofen is a non-steroidal drug that has analgesic and anti-inflammatory properties. Dexindoprofen is the dextrorotatory stereo-isomer of indoprofen, to which it has a similar adverse effect pattern. Gastrointestinal and nervous system effects and skin reactions are the most frequent. Following reports of severe gastrointestinal bleeding and carcinogenicity in animals indoprofen was withdrawn from the market worldwide.

Etersalate is a derivative of aspirin exerting antiplatelet, analgesic, anti-inflammatory and antipyretic properties. Etersalate has potential to prevent oligomerization of amyloid beta (Aβ) peptides.

Levophacetoperane is a piperidine derivative. Levofacetoperane is a sympathomimetic central nervous system stimulant and is commonly used to treat depression. Levophacetoperane is also a known analeptic and is strongly linked to apnea reversal in dogs after a single intravenous injection.

Livoletide (AZP-531) is an analog of unacylated ghrelin, a naturally occurring hormone that is thought to counteract the effects of acylated ghrelin. The drug was designed to improve glycaemic control and reduce weight. Livoletide participated in pivotal phase 2b/3 clinical study for the treatment of Prader-Willi syndrome. In addition, the drug was studied in patients with type 2 diabetes mellitus (T2D). Its pharmacokinetic profile, suitable for once daily dosing, and metabolic effects support further clinical development for T2D.

Delergotrile is a derivative of ergot alkaloids with dopaminergic and anti-parkinsonian action. Delergotine shows neuropharmacological action typical of postsynaptic dopamine D1 receptor stimulants, in particular in the extrapyramidal system. In addition, delergotine stimulates adenylate cyclase coupled serotonin receptors and antagonize central alpha-adrenergic receptors. The compound was studied in the clinical trials, in new, non-levodopa-treated parkinsonian patients. Delergotine elicited a significant but mostly only mild or moderate antiparkinsonian efficacy which seems to be less than that of levodopa.

Palinavir (formerly BILA2011BS) is a potent inhibitor of the human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) proteases and was studied for the treatment of HIV infections. However, information about the current development of this drug is not available.

Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.